Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3

D Dwight H. Owen N Nofisat Ismaila (American Society of Clinical Oncology (ASCO), Alexandria, VA, US) A Amith Ahluwalia (Confluence Health Wenatchee Valley Hospital and Clinics, Wenatchee, WA) J Jill Feldman (Patient Advocate EGFR Resisters Deerfield Illinois USA) S Shirish Gadgeel (Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI) M Michael Mullane (Aurora Cancer Care, Mount Pleasant, WI) J Jarushka Naidoo (3Beaumont RCSI Cancer Centre, Dublin, Ireland) C Carolyn J. Presley J Joshua E. Reuss (Georgetown University, Washington, DC) E Eric K. Singhi (University of Texas MD Anderson Cancer Center, Houston, TX) J Jyoti D. Patel (Tempus AI, Chicago, IL)

Abstract

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .

Article Details

Volume / Issue Vol. 43, Issue 10
Published April 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

D

Dwight H. Owen

N

Nofisat Ismaila

American Society of Clinical Oncology (ASCO), Alexandria, VA, US

A

Amith Ahluwalia

Confluence Health Wenatchee Valley Hospital and Clinics, Wenatchee, WA

J

Jill Feldman

Patient Advocate EGFR Resisters Deerfield Illinois USA

S

Shirish Gadgeel

Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI

M

Michael Mullane

Aurora Cancer Care, Mount Pleasant, WI

J

Jarushka Naidoo

3Beaumont RCSI Cancer Centre, Dublin, Ireland

C

Carolyn J. Presley

J

Joshua E. Reuss

Georgetown University, Washington, DC

E

Eric K. Singhi

University of Texas MD Anderson Cancer Center, Houston, TX

J

Jyoti D. Patel

Tempus AI, Chicago, IL